EXHIBIT 1.

Relative Risk (RR) Reduction Of Cardiovascular Disease, By Statin Prescription Length

	Prescription length (days)
	30		60		90
	RR reduction	Reported 95% CI	RR reduction	Sensitivity analysis	RR reduction	Sensitivity analysis
primary prevention
MI	0.77	(0.74, 0.80)	0.73	(0.72, 0.75)	0.71	(0.70, 0.74)
CVA	0.83	(0.78, 0.88)	0.80	(0.80, 0.81)	0.79	(0.80, 0.81)
secondary prevention
MI	0.76	(0.73, 0.79)	0.72	(0.71, 0.74)	0.70	(0.70, 0.73)
CVA	0.85	(0.81, 0.90)	0.82	(0.82, 0.83)	0.81	(0.80, 0.83)
Death	0.85	(0.77, 0.95)	0.83	(0.83, 0.84)	0.82	(0.81, 0.83)

source Authors' analysis of data from the following sources: Baigent C et al. Efficacy and safety of cholesterol-lowering treatment (Note 30 in text); Mihaylova B et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease (Note 31 in text); and Batal HA et al. Impact of prescription size on statin adherence and cholesterol levels (Note 10 in text). notes Primary prevention is the prevention of onset of symptomatic disease. Secondary prevention is the use of medication after a patient has survived a cardiovascular disease event. CI is confidence interval. MI is myocardial infarction. CVA is cerebrovascular accident (stroke).